Nikitha Naomi Dsouza, Varun Alampady, Krishnaprasad Baby, Swastika Maity, Bharath Harohalli Byregowda, Yogendra Nayak
The "Thalidomide tragedy" is a landmark in the history of the pharmaceutical industry. Despite limited clinical trials, there is a continuous effort to investigate thalidomide as a drug for cancer and inflammatory diseases such as rheumatoid arthritis, lepromatous leprosy, and COVID-19. This review focuses on the possibilities of targeting inflammation by repurposing thalidomide for the treatment of idiopathic pulmonary fibrosis (IPF). Articles were searched from the Scopus database, sorted, and selected articles were reviewed...
March 25, 2023: Inflammopharmacology
Natalie Burgos Bencosme, Jorge Eduardo Herrera Parra, Eva María López Álvarez, José Gutiérrez Rodríguez
No abstract text is available yet for this article.
March 23, 2023: Revista Española de Geriatría y Gerontología
Jasneet Kaur, Sai Sudha Valisekka, Maha Hameed, Pushyami Satya Bandi, Samyukta Varma, Chibuzor Joseph Onwughalu, Hany Ibrahim, Himani Mongia
Monoclonal Gammopathy of Undetermined Significance (MGUS) is an asymptomatic premalignant plasma cell dyscrasia with a predominate rise of the IgG immunoglobulin fraction without end-organ damage, often diagnosed incidentally. Despite its progression into various subsequent forms of hematological malignancies, MGUS remains underdiagnosed. A literature search was conducted using the Medline, Cochrane, Embase, and Google Scholar databases, including articles published until December 2022. Keywords used encompassed "Monoclonal Gammopathy of Undetermined Significance," "Plasma Cell dyscrasia," "Monoclonal gammopathy of renal significance," and "IgM Monoclonal gammopathy of Undetermined Significance," This study aimed to conduct a critical review to update knowledge regarding the pathophysiology, risk factors, clinical features, diagnostic protocols, complications, and current and novel treatments for MGUS...
February 23, 2023: Clinical Lymphoma, Myeloma & Leukemia
Brian M Russell, David E Avigan
Immune dysregulation is a hallmark of clinically active multiple myeloma (MM). Interactions between malignant clonal cells and immune cells within the bone marrow microenvironment are associated with the formation of a milieu favorable to tumor progression. IL-10, TGF-β and other immunoregulatory pathways are upregulated, promoting angiogenesis, tumor cell survival and inhibition of the native immune response. Transcriptomic evaluation of the bone marrow microenvironment reveals polarization of the T cell repertoire towards exhaustion and predominance of accessory cells with immunosuppressive qualities...
March 25, 2023: International Journal of Hematology
Fen Saj, Yadav Nisha, Prasanth Ganesan, Smita Kayal, Rakhee Kar, Dhanapathi Halanaik, Biswajit Dubashi
Bortezomib, lenalidomide, and dexamethasone induction chemotherapy (VRd), followed by autologous stem cell transplantation (ASCT), are the standard of care for patients with newly diagnosed multiple myeloma (NDMM). Pomalidomide is currently approved for relapsed-refractory multiple myeloma. This single-arm, open-label, phase 2 study was the prospective evaluation of the efficacy and safety of bortezomib, pomalidomide, and dexamethasone (VPd) induction for NDMM. We used Fleming's two-stage design for sample size calculation...
March 24, 2023: Blood Cancer Journal
Ali Ozan Oner, Çiğdem Özdemir, Filiz Yavaşoğlu, Yiğit Şenol, Sena Naz Adsız
PURPOSE: The aim of this study was to determine the power of the SUVmax value obtained from 18 F-FDG PET/CT in multiple myeloma (MM) patients to be able to predict immunophenotype characteristics (CD20, CD44, CD56, CD117, CD138 antigen expressions), bone marrow fibrosis, cyclin D1 oncogene, and M-protein subtypes which play a role in diagnosis-treatment and prognosis of the disease. MATERIAL AND METHOD: The study included 54 patients with multiple myeloma who underwent PET/CT for initial staging and bone marrow biopsy...
March 22, 2023: Revista española de medicina nuclear e imagen molecular
Alessia Zinzi, Mario Gaio, Valerio Liguori, Cecilia Cagnotta, Donatella Paolino, Giuseppe Paolisso, Giuseppe Castaldo, Gianfranco Nicoletti, Francesco Rossi, Annalisa Capuano, Concetta Rafaniello
Chimeric Antigen Receptor (CAR)-modified T lymphocytes represent one of the most innovative and promising approaches to treating hematologic malignancies. CAR-T cell therapy is currently being used for the treatment of relapsed/refractory (r/r) B-cell malignancies including Acute Lymphoblastic Leukemia, Large B-Cell Lymphoma, Follicular Lymphoma, Multiple Myeloma and Mantle Cell Lymphoma. Despite the unprecedented clinical success, one of the major issues of the approved CAR-T cell therapy - tisagenlecleucel, axicabtagene, lisocabtagene, idecabtagene, ciltacabtagene and brexucabtagene - is the uncertainty about its persistence which in turn could lead to weak or no response to therapy with malignancy recurrence...
March 22, 2023: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
Philippe Moreau, Niels W C J van de Donk, Michel Delforge, Hermann Einsele, Valerio De Stefano, Aurore Perrot, Britta Besemer, Charlotte Pawlyn, Lionel Karlin, Salomon Manier, Xavier Leleu, Katja Weisel, Francesca Ghilotti, Joris Diels, Ahmed Elsada, Raul Morano, Vadim Strulev, Lixia Pei, Rachel Kobos, Jennifer Smit, Mary Slavcev, Maria-Victoria Mateos
INTRODUCTION: Patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE-RRMM) have a poor prognosis and limited treatment options. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, was studied in patients with TCE-RRMM in the single-arm MajesTEC-1 study. To assess the relative effectiveness of teclistamab versus real-world physician's choice of therapy (RWPC), adjusted comparisons were performed using individual patient data from MajesTEC-1 and LocoMMotion, a prospective study of patients with TCE-RRMM...
March 24, 2023: Advances in Therapy
Aimee Merino, Joseph Maakaron, Veronika Bachanova
Natural Killer (NK) cells yield promise in therapy of hematologic malignancies. The clinical experience with adoptively transferred allogeneic NK cells over past two decades has revealed safety and minimal risk of CRS or ICANS. Unlike T cells which have to be genetically altered to avoid graft vs host disease (GVHD), HLA mismatched NK cells can be infused without GVHD risk. This makes them ideal for the development of off-the-shelf products. In this review we focus on NK biology relevant to the cancer therapy, the trajectory of NK therapeutics for leukemia, lymphoma, and myeloma; and advantages of the NK cell platform...
March 12, 2023: Blood Reviews
Shuku Sato, Shun Tsunoda, Teiko Kawahigashi, Wataru Kamata, Yotaro Tamai
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard treatment for symptomatic multiple myeloma (MM) in patients under 65 years of age. However, the performing of ASCT in older patients > 65 years without comorbidities or complications is controversial. Introduction of novel drugs, such as daratumumab, has improved the long-term survival of patients with MM who are ineligible for ASCT. This retrospective study aimed to evaluate the clinical significance of ASCT in older patients, even in the era of novel drugs...
March 23, 2023: Annals of Hematology
Eun Hee Jung, Ja Min Byun, Dong-Yeop Shin, Young Rok Do, Jae-Cheol Jo, Sang Min Lee, Sung-Soo Yoon
BACKGROUND: Current guidelines recommend using filgrastim or tbo-filgrastim to mobilize hematopoietic progenitor cells in an autologous setting. However, previous studies have suggested other forms of granulocyte colony-stimulating factor (G-CSF) are equally efficacious, possibly with fewer leukaphereses required. Thus, we prospectively studied the efficacy of lenograstim, a glycosylated recombinant form of G-CSF, in multiple myeloma (MM) patients. METHODS: From November 2011 to January 2020, 98 MM patients undergoing autologous stem cell transplant (ASCT) from five academic centers in Korea were enrolled...
March 23, 2023: Cancer Medicine
Nancy Wilson, Shannon Reese, Lucy Ptak, Fahad Aziz, Sandesh Parajuli, Vadim Jucaud, Shari Denham, Ameet Mishra, Marilia Cascalho, Jeffrey L Platt, Peiman Hematti, Arjang Djamali
BACKGROUND: Ixazomib is a second-generation oral proteasome inhibitor approved for treatment of refractory multiple myeloma. We conducted an open label phase II trial, IXADES (IXAzomib for DESensitization) testing safety of Ixazomib treatment as an approach to decreasing the level and diversity of specificities of anti-HLA antibodies in subjects awaiting kidney transplantation. The trial (NCT03213158) enrolled highly sensitized kidney transplant candidates, defined as subjects with calculated panel reactive antibodies (cPRA) >80%, awaiting kidney transplantation >24 months...
March 23, 2023: Kidney360
Sophia Ascione, Stéphanie Harel, Florent L Besson, Rakiba Belkhir, Julien Henry, Bruno Royer, Bertrand Arnulf, Xavier Mariette, Raphaèle Seror
Not available.
March 23, 2023: Haematologica
Carlos A Monroig-Rivera, Clara N Finch Cruz
IgA plasma cell myeloma (PCM) has been linked to molecular abnormalities that confer a higher risk for adverse patient outcomes. However, since IgA PCM only accounts for approximately 20% of all PCM, there are very few reports on high-risk IgA PCM. Moreover, no such reports are found on the more infrequent biclonal IgA PCM. Hence, we present a 65-year-old Puerto Rican female with acute abdominal pain, concomitant hypercalcemia, and acute renal failure. Protein electrophoresis with immunofixation found high IgA levels and detected a biclonal IgA gammopathy with kappa specificity...
March 2023: Journal of Pathology and Translational Medicine
Jing Huang, Fengping Qiu, Huiqi Zhang, Xiangli Shen, Xia Lin
OBJECTIVE: To evaluate the clinical efficacy of continuous veno-venous hemofiltration (CVVH) combined with hemoperfusion for the treatment of multiple myeloma (MM) complicated with acute kidney injury (AKI). METHODS: Medical records of 73 patients with MM complicated with AKI admitted to the First People's Hospital of Huzhou from January 2019 to January 2021 were retrospectively analyzed. According to the treatment records, 35 patients received simple chemotherapy (control group), and 38 patients received CVVH combined with HP on the basis of chemotherapy (observation group)...
2023: Pakistan Journal of Medical Sciences Quarterly
Xiaolei Wei, Yongqiang Wei
Among hematological malignancies, multiple myeloma (MM) represents the leading indication of autologous hematopoietic stem cell transplantation (auto-HCT). Auto-HCT is predominantly performed with peripheral blood stem cells (PBSCs), and the mobilization and collection of PBSCs are essential steps for auto-HCT. Despite the improved success of conventional methods with the incorporation of novel agents for PBSC mobilization in MM, mobilization failure is still a concern. The current review comprehensively summarizes various mobilization strategies for mobilizing PBSCs in MM patients and the evolution of these strategies over time...
March 22, 2023: Annals of Hematology
W Y Huang, W Liu, H M Liu, Y Xu, Q Wang, C X Du, W J Xiong, W W Sui, F Tian, J Wang, S H Yi, G An, L G Qiu, D H Zou
No abstract text is available yet for this article.
February 14, 2023: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
Y H Song, F J Zhang, R R Hu, M Chen, C Yang, W Wang, Y Qin, D B Zhou, J L Zhuang
Objective: To investigate the causative factors of renal function in newly diagnosed multiple myeloma (MM) patients with renal inadequacy. Methods: 181 MM patients with renal impairment from August 2007 to October 2021 at Peking Union Medical College Hospital were recruited, whose baseline chronic kidney disease (CKD) stage was 3-5. Statistical analysis was performed based on laboratory tests, treatment regimens, hematological responses, and survival among various renal function efficacy groups. A logistic regression model was employed in multivariate analysis...
February 14, 2023: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
Ajil Shaji, Pavithran Keechilat, Vijaykumar Dk, Catherine Sauvaget
PURPOSE: Cancer mortality trends have not been documented across the population of India. We, therefore, analyzed the overall and individual cancer mortality trends for 23 major cancers between 2000 and 2019 on the basis of Global Health Observatory (GHO) database. MATERIALS AND METHODS: This study examined cancer mortality trends for 23 major cancer sites on the basis of 12.85 million cancer deaths obtained from the GHO of the WHO between 2000 and 2019. A joinpoint regression model was used to analyze the long-term trends of cancer mortality...
March 2023: JCO global oncology
Alexey Surov, Franz Benkert, Wolfram Pönisch, Hans-Jonas Meyer
OBJECTIVES: Body composition assessment is comprised by skeletal muscle mass (SMM) and subcutaneous and visceral adipose tissue (SAT and VAT) and can be quantified by imaging. It can be predictive of several clinically outcomes in patients with hematological diseases. Our aim was to establish the effect of body composition parameters on overall survival (OS) and progression-free survival (PFS) in patients with multiple myeloma (MM). MATERIALS AND METHODS: All patients with MM were retrospectively analyzed between 2009 and 2019...
December 2023: Hematology (Amsterdam, Netherlands)
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.